Latest Breast Cancer Therapeutics Stories

MOUNTAIN VIEW, Calif., May 16, 2012 /PRNewswire/ -- Although there are approximately 27 drugs on the market indicated for the treatment of breast cancer, there is currently an unmet need to treat patients. Consequently, there are abounding opportunities for pharmaceutical manufacturers, as breast cancer is the second most common cancer among women. There are currently 55 breast cancer therapeutic drugs in the developmental phase in the U.S., with additional drugs expected...

SYDNEY, Aug. 5 /PRNewswire/ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia's female population, the total number of breast cancer patients in the country was 164,814 in 2008. This figure is estimated to reach 304,511 patients by 2013. Globally, breast cancer is second to lung cancer as the cause of death among women. (Logo:...

Rising public awareness about breast cancer and the treatments available has greatly improved revenues in the overall breast cancer therapeutics market. To thrive in this highly competitive market, drug developers must offer drugs that improve survival rates and the quality of life. New analysis from Frost & Sullivan (http://www.pharmaceuticals.frost.com), U.S. Breast Cancer Therapeutics Markets, finds that the targeted therapies segment of the market earned revenues of $1.34 billion in...